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Background: TNBC represents a heterogeneous subgroup of BC with poor prognosis and frequently resistant to CT.
Material and methods: The relationship between Bcl2 immunohistochemical protein expression and clinico-
pathological outcomes was assessed in 736 TNBC-patients: 635 patients had early primary-TNBC (EP-TNBC) and 101
had primary locally advanced (PLA)-TNBC treated with neo-adjuvant- ATC-CT.
Results: Negative Bcl2 (Bcl2-) was observed in 70% of EP-TNBC and was signiﬁcantly associated with high
proliferation, high levels of P-Cadherin, E-Cadherin and HER3 (P’s < 0.01), while Bcl2+ was signiﬁcantly associated with
high levels of p27, MDM4 and SPAG5 (P < 0.01). After controlling for chemotherapy and other prognostic factors, Bcl2-
was associated with 2-fold increased risk of death (P = 0.006) and recurrence (P = 0.0004). Furthermore, the prognosis of
EP-TNBC/Bcl2- patients had improved both BC-speciﬁc survival (P = 0.002) and disease-free survival (P = 0.003), if they
received adjuvant-ATC-CT. Moreover, Bcl2- expression was an independent predictor of pathological complete response
of primary locally advanced triple negative breast cancer (PLA-TNBC) treated with neoadjuvant-ATC-CT (P = 0.008).
Conclusion: Adding Bcl2 to the panel of markers used in current clinical practice could provide both prognostic and
predictive information in TNBC. TNBC/Bcl2- patients appear to beneﬁt from ATC-CT, whereas Bcl2+ TNBC seems to be
resistant to ATC-CT and may beneﬁt from a trial of different type of chemotherapy with/without novel-targeted agents.
Key words: anthracyclin chemotherapy, Bcl2, predictive marker, prognostic marker, theraputic targets, triple negative
breast cancer
introduction
BC is the most commonly occurring cancer in women. One
hundred and seventy thousand (12.2%) of the newly 1.38
million diagnosed BC cases each year are deﬁned TNBC [1, 2].
TNBC represents a subgroup of BCs that lack signiﬁcant
expression of estrogen receptor (ER), progesterone receptor
(PR) and human epidermal growth factor-2 (HER2) TNBCs are
generally considered to be aggressive tumours that often occur
at a young age [3]. Recent studies, however, suggest that TNBC
may represent a heterogeneous group of tumours with regards
to gene expression, clinical presentation, epidemiology,
histology, radiology, prognosis and response to treatment [2–5].
The management of TNBC remains a signiﬁcant clinical
challenge, hindered by the inability of these tumours to respond
to targeted therapeutic agents [2–4]. As TNBC appears to
represent a more diverse population than originally thought,
further sub-stratiﬁcation may help identify patients with a
subtype of TNBCmore or less likely to respond to chemotherapy.
Recent studies have shown Bcl2 protein and gene expression
to be a promising prognostic and predictive marker in human
cancers [6–17] especially in hormone receptor-positive, node-
negative BC [16, 17]. High Bcl2 level is associated with
improved BC outcome.
The role of Bcl2 in TNBC, however, is not well deﬁned. In
addition, few studies have investigated the association between
Bcl2 status and response to chemotherapeutic agents, including
anthracycline in BC patients [10]. For instance, in diffuse large
B-cell lymphoma (DLBCL) with MYC/Bcl2 co-expression a
worse prognosis was seen in patients treated with an ATC-CT
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(R-CHOP; Rituximab-cyclophosphamide, doxorubicin,
vincristine and prednisolone).
In this study, we have investigated the role of Bcl2 as a
prognostic marker in a large cohort of TNBC. We have also
studied the role of Bcl2 as a surrogate predictive marker of
response to chemotherapy prescribed in the adjuvant or neo-
adjuvant setting in patients with either early primary-TNBC
(EP-TNBC) or primary locally advanced triple negative breast
cancer (PLA-TNBC).
materials andmethods
For materials and methods section, see supplementary material, available at
Annals of Oncology online.
results
early primary-TNBC cohort
EP-TNBC patients were all female and their median age was 51
years (range 28–71 years). Their median follow-up was 107
months (range 2–243 months).
clinico-pathological features of bcl2 expression in EP-TNBC.
Negative Bcl2 expression (Bcl2-; Figure 1C–E) was observed in
421 of 600 (70.2%) of EP-TNBC tumours and was signiﬁcantly
associated with high mitotic index (P = 0.005), high levels of
P-Cadherin (P = 0.007), E-Cadherin (P = 0.045), CK 19
(P = 0.001) and HER3 (P < 0.0001). While Bcl2 positive
expression (Bcl2+) was signiﬁcantly associated with high
expression of p27 (P = 0.01), MDM4 (P < 0.0001), and sperm
associated antigen 5 (SPAG5; P = 0.004) (Table 1).
bcl2 is an independent prognostic biomarker in EP-TNBC.
Bcl2- was strongly associated with an adverse outcome at 10
years and nearly doubles the risk of death from EP-BC (HR
1.71; 95% conﬁdence interval (CI) 1.21–2.41; P = 0.002) and
recurrence (HR 1.79; 95% CI 1.34–2.38; P = 0.0005);
(Figure 1F–H). After controlling for chemotherapy, traditional
pathological prognostic factors and other potential confounders,
Bcl2 was conﬁrmed as an independent prognostic factor for
both DFS (HR 1.69; 95% CI 1.26–2.27; P = 0.0004) and BCSS
(HR 1.64; 95% CI 1.15–2.32; P = 0.006) at 10 years (Table 2).
The EP-TNBC cohort was further subdivided into three patient
Figure 1. (A–E) Microphotographs of Bcl2 expression in normal breast tissue showing strong cytoplasmic expression in the neoplastic cells and in the stromal
cells (A), breast cancer tissue (B–E) showing complete absence of any staining in both neoplastic and stromal cells (C), negative expression of Bcl2 in the
neoplastic cells, with few positive stromal lymphocyte cells reaction (D), negative expression of Bcl2 in the neoplastic cells with positive stromal extensive
lymphocyte reaction (E) (magniﬁcation × 200). (F–H): Kaplan–Meier curves showing breast cancer-speciﬁc survival (F) and disease-free survival (H) in the
primary operable triple negative breast cancer (PO-TNBC). See text for details.
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groups based on the chemotherapy given: (i) no chemotherapy
(supplementary Figure S1A–B, available at Annals of Oncology
online), (ii) CMF (Supplementary Figure S1C–D, available at
Annals of Oncology online) or (iii) anthracycline-combination
(FEC – 5FU, epirubicin, cyclophosphamide) (supplementary
Figure S1E–F, available at Annals of Oncology online). Again
Bcl2- was associated with approximately twice the risk of
death from EP-BC (HR 2.25; 95% CI 1.40–3.59; P = 0.001) and
also of recurrence (HR 2.45; 95% CI 1.61–3.71; P = 0.00002)
in patients who did not receive chemotherapy. In patients
treated with CMF a signiﬁcant association was demonstrated
between Bcl2 status and clinical outcome; Bcl2- had a shorter
DFS (log rank 2.66, P = 0.031) and BCSS (log rank 3.43,
P = 0.05).
bcl2 is a predictor of outcome after adjuvant ATC-CT. In EP-
TNBC patients who received ATC-CT, Bcl2- tumours had a
clinical outcome similar to those with Bcl2+ phenotype
(supplementary Figure S1E–F, available at Annals of Oncology
online). Both BCCS and DFS were longer in Bcl2- patients
treated with an ATC-CT when compared with those Bcl2-
patients who didn’t receive chemotherapy or who were treated
with CMF (Figure 2A–D).
Bcl2-TNBC patients had prolonged BCSS and DFS when they
were exposed to ATC-CT compared with those who either
received CMF or did not received any chemotherapy
(Figure 2A–D). For example 42% of patients who were Bcl2-
and either did not receive any chemotherapy or received CMF
had died of BC at 10 years compared with 25% of Bcl2- patients
who were treated with ATC-CT. For Bcl2-/TNBC patients,
exposure to ATC-CT reduced the risk of death (HR 0.53; 95% CI
0.35–0.80, P = 0.002) and recurrence (HR 0.61; 95% CI 0.44–
0.84, P = 0.003) by 40%–50%.
No beneﬁt was demonstrated from prescribing ATC-CT in
Bcl2+ EP-TNBC (supplementary Figue S2A–C, available at
Annals of Oncology online). Even those of high-risk (NPI >3.4)
Bcl2+ EP-TNBC patients who were exposed to ATC-CT had
double the risk of recurrence (HR 1.85; 95% CI 1.03–3.34,
Table 1. Clinico-pathological characteristics of Bcl2 protein expression in
primary operable triple negative breast cancer (n = 600)
Variables Bcl2 protein expression P–value
Negative
(n = 421)
Positive
(n = 179)
Mitotic index
M1 (low; mitoses <10) 19 (4.5) 16 (8.9) 0.005**
M2 (medium; mitoses 10–18) 54 (12.9) 10 (5.6)
M3 (high; mitoses >18) 346 (82.6) 153 (85.5)
P27
Negative 272 (85.3) 89 (74.8) 0.01**
Positive 47 (14.7) 30 (25.2)
SPAG5
Negative 151 (44.9) 42 (30.7) 0.004**
Positive 185 (55.1) 95 (69.3)
HER3
Negative 194 (56.1) 105 (72.9) <0.0001**
Overexpression 152 (43.9) 39 (27.1)
MDM4
Negative 337 (96.3) 127 (85.4) <0.0001**
Overexpression 14 (3.7) 22 (14.6)
CK19
Negative 25 (12.1) 23 (28.8) 0.001**
Positive 182 (87.9) 57 (71.3)
E-cadherin
Negative 107 (29.3) 59 (38.3) 0.045**
Positive 258 (70.7) 95 (61.7)
P-cadherin
Negative 45 (13) 33 (22.9) 0.007**
Positive 300 (87) 111 (77.1)
Tumour grade
G1 2 (0.5) 5 (2.8) 0.055
G2 34 (8.1) 14 (7.8)
G3 383 (91.4) 160 (89.4)
Tumour size
T1 a + b (≤1.0) 25 (6) 13 (7.5)
T1 c (>1.0–2.0) 183 (43.9) 77 (44.3) 0.577
T2 (>2.0–5.0) 187 (44.8) 79 (45.4)
T3 (>5) 22 (5.3) 5 (2.9)
Lymph node stage
Negative 273 (65.0) 121 (67.6) 0.237
Positive (1–3 nodes) 100 (23.8) 46 (25.7)
Positive (>3 nodes) 47 (11.2) 12 (6.7)
Tumour type
IDC-NST 346 (86.5) 133 (79.6) 0.225
Medullary/atypical 23 (5.8) 5 (3.0)
Tubular carcinoma 5 (1.3) 11 (6.6)
Invasive lobular carcinoma 12 (3.0) 9 (5.4)
Others 14 (3.5) 9 (5.4)
Lymphovascular invasion
Yes 212 (50.5) 85 (48.0) 0.584
No 208 (49.5) 92 (52.0)
EGFR
Negative 197 (53.5) 90 (59.2) 0.236
Overexpression 171 (46.5) 62 (40.8)
HER4
Negative 131 (37.4) 60 (40.5) 0.514
Overexpression 219 (62.6) 88 (59.5)
Continued
Table 1. Continued
Variables Bcl2 protein expression P–value
Negative
(n = 421)
Positive
(n = 179)
P53
Negative 167 (42.3) 67 (42.4) 0.978
Positive 228 (57.7) 91 (57.6)
Ki67
Negative 51 (13.4) 27 (16.7) 0.324
Positive 329 (86.6) 135 (83.3)
BRCA1
Negative 218 (64.9) 81 (58.7) 0.205
Positive 118 (35.1) 57 (41.3)
Basal like phenotype
No 126 (34.9) 56 (38.4) 0.463
Yes 235 (65.1) 90 (61.6)
**Statistically signiﬁcant.
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P = 0.041) compared with those who did not (Supplementary
Figue S2D, available at Annals of Oncology online).
p LA-TNBC patients treated with neoadjuvant
ATC-CT
All LA-TNBC patients were female and their mean age was 51
years (range 25–76 years). All patients received neoadjuvant
ATC-CT either without (67 of 101; 66.3%) or with Taxane (34
of 101; 33.7%) [supplementary Table S2, available at Annals of
Oncology online]. Sixty-seven of 101(66.3%) of patients received
six cycles of an anthracycline-based therapy (FEC: 5-
ﬂuorouracil (5-FU) 500 mg m−2, epirubicin 75–100 mg m−2,
cyclophosphamide 500 mg m−2, on day 1 of a 21-day cycle).
Patients were scheduled to undergo surgery 4 weeks after the
sixth cycle. Twenty-eight of 101 (27.7%) of LA-TNBC patients
achieved pCR.
bcl2 is a predictor of outcome in patients who receive
neoadjuvant ATC-CT. Among 101 patients with PLA-TNBC
treated with neoadjuvant ATC-CT, 52 of 101 (51.5%) were Bcl2-.
Twenty-one of 52 (40%) of TNBC patients with Bcl2- achieved
a pCR versus 7 of 49 (14%) of those with Bcl2+ (P = 0.003).
Similar to the situation in adjuvant setting, LA-TNBC patients
who received neoadjuvant ATC-CT, Bcl2- tumours who
achieved a pCR had a clinical outcome similar to those with
Bcl2+ phenotype (Supplementary Figue S3C, available at Annals
of Oncology online). In contrast, among 73 patients who had
residual disease after neoadjuvant ATC-CT, 31 patients with
Bcl2- had a worse BCSS (HR 2.39; 95% CI 1.15–4.98, P = 0.02)
and DFS (HR 2.4; 95% CI 1.16–5.04, P = 0.018) compared with
those with Bcl2+ expression (supplementary Figue S3D,
available at Annals of Oncology online).
Multivariate regression analysis, after controlling for patient
age at diagnosis, tumour stage, grade, size and p53 status,
showed that Bcl2-expression is an independent predictor of pCR
of LA-TNBC (HR 4.53; 95% CI 1.5–13.8 P = 0.008);
(supplementary Figue S3B, available at Annals of Oncology
online).
discussion
TNBC encompasses a subpopulation of BC patients
traditionally considered to have a poor prognosis [3].
Neither the classical pathological variables nor the modern
molecular assays, have shown prognostic value in this patient
group [2–5, 17]. Current research is focused on the
identiﬁcation of biological markers that could be used to tailor
treatment to individual patients with TNBC. The results of our
study show Bcl2 to be a promising prognostic and predictive
marker in TNBC. This adds to an increasing body of evidence
to support that routine assessment of Bcl2 status in TNBC
patients may reﬁne the outcome, both as a prognostic and
predictive factor.
Although the potential importance of Bcl2 as a prognostic
factor in BC has been investigated in previous studies [8, 9, 15,
16], our study has reported the prognostic importance of this
marker in a large number of TNBC cases (over 700 patients).
Table 2. Multivariate analysis using Cox regression analysis conﬁrms that Bcl2 protein expression and lymph node stage are independent prognostic factors in
triple negative breast cancer
Clinico-pathological variables Breast cancer-speciﬁc survival at 10 years Progression-free survival at 10 years
HR (95% CI) P-value HR (95% CI) P-value
Bcl2 expression
High 1 0.006** 1 0.0004**
Low 1.64 (1.15–2.32) 1.69 (1.26–2.27)
Lymph node stage
Negative 1 0.001** 1 2.2 × 10−8**
Positive (1–3 nodes) 1.13 (0.81–1.60) 1.17 (0.88–1.56)
Positive (>3 nodes) 2.23 (1.48–3.37) 2.79 (1.98–3.91)
Tumour grade
Grade 1(low) 1 0.739 1 0.999
Grade 2 (intermediate) 0.69 (1.14–3.39) 1.03 (0.29–3.63)
Grade 3 (high) 0.89 (0.15–5.28) 1.04 (0.25–4.29)
Tumour size (continuous) 1.01 (0.97–1.04) 0.620 1.01 (0.98–1.040) 0.593
Lymphovascular invasion
No 1 0.325 1 0.582
Yes 0. 87 (0.65–1.16) 0.93 (0.73–1.19)
Mitotic index
M1 (low; mitoses <10) 1 0.319 1 0.503
M2 (medium; mitoses 10–18) 1.55 (0.57–4.22) 1.24 (0.58–2.65)
M3 (high; mitoses >18) 1.14 (0.38–3.41) 0.99 (0.42–2.32)
Chemotherapy
No 1 0.006** 1 0.109
Yes 0.78 (0.65–0.93) 0.89 (0.77–1.03)
**Statistically signiﬁcant.
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We have shown that loss of Bcl2 nearly doubles the risk of both
death and recurrence from TNBC in agreement with earlier
studies in mixed BC cohorts [8, 9, 15, 16]. Contrary to our
ﬁndings, Tawﬁk et al. found Bcl2+ TNBC had a worse prognosis
than Bcl2-TNBC. The reason for these differences is not clear
but the smaller patient sample, differences in treatment
protocols or other factors in the study by Tawﬁk et al. may
play a role.
Our study has also shown that Bcl2 status could help predict
the outcome of treatment. In Bcl2-/TNBC patients, both BCSS
and DFS are improved if patients are treated with an
anthracycline. This association is not seen in Bcl2+/TNBC
patients. In fact in the latter population there is some evidence
to suggest that these patients have worse DFS when treated with
an anthracycline. Similar results have been reported by
Bouchalova et al. who analysed the response to AC-ACT in a
small cohort of TNBC patients. The ﬁndings of this study are
in agreement with our results demonstrating that high Bcl2
expression is associated with worse relapse free and overall
survival (OS) in patients treated with adjuvant anthracycline-
based treatment. Again the results from the multivariate
analysis of this study show Bcl2 status, size and LN stage to be
predictive of both OS and DFS [26] in common with our
ﬁndings. Furthermore, similar associations have been seen
between Bcl2 status and anthracycline response in other
tumours. For example DLBCL patients with both MYC and
Bcl2 co-expression had a worse DFS and OS when treated with
standard R-CHOP chemotherapy [6].
Interestingly in our study the beneﬁt from chemotherapy in
the Bcl2- patient group was only seen when they were treated
with an anthracycline and not from CMF. All patients who
received an anthracycline-based regimen will have been given
FEC- combination. As FEC contains 5-FU and
cyclophosphamide in common with CMF the only different
agent between the two regimens is the anthracycline, in this case
epirubicin. The signiﬁcant difference observed between the no
chemotherapy/CMF group and the anthracycline treated group
is therefore most likely due to the addition of epirubicin,
although could be a combination effect of the drugs used.
Recently, Buchholz et al. found that 27% of Bcl-2 negative BC
had achieved pCR to Doxorubicin-based neoadjuvant
chemotherapy versus 4% of Bcl-2 positive (P = 0.004).
We have shown Bcl2-expression to be an independent
predictor of pCR in PLA-TNBC. Bcl2-/TNBC patients were
Figure 2. Kaplan–Meier curves showing breast cancer-speciﬁc survival (BCSS) and disease-free survival (DFS) in high-risk (NPI > 3.4) Bcl2 negative primary
operable triple negative breast cancer (Bcl2-/PO-TNBC) stratiﬁed according to the received adjuvant chemotherapy protocols; No chemotherapy, CMF and
anthracycline (A–B). As no signiﬁcant difference was seen between either BCSS or DFS in high-risk Bcl2 negative patients treated with CMF when compared
with no chemotherapy, we chose to combine the no chemotherapy/CMF groups and to compare this new combination group with patients who received an
anthracycline-based regimen (C–D). See text for details.
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signiﬁcantly more likely to have a pCR than patients with Bcl2+
expression. These ﬁndings are similar to early reports in mixed
BC cohorts (i.e. both TNBC and non-TNBC [7]. Von
Minckwitz et al also found Bcl2- to be associated with pCR in
patients with primary-BC treated with dose-dense doxorubicin
and docetaxel chemotherapy with or without endocrine
treatment. As a pCR following neoadjuvant ATC-CT has been
shown to be associated with an improved outcome, our ﬁndings
suggest that staining for Bcl2 status in TNBC patients could
help identify a cohort of patients who would be ideal for
neoadjuvant ATC-CT.
As evidenced by our results, and those from earlier studies,
patients with Bcl2-/TNBC tumours gain signiﬁcant beneﬁt from
anthracycline treatment. The explanation behind this ﬁnding is
likely to be complex and involve the multiple functions of Bcl2.
The Bcl2 protein acts as both an anti-apoptotic factor and also
prolongs cell cycle at G0 [11, 13, 14], and therefore, Bcl2+ cells
are more likely to recover from damage caused by
chemotherapy. Bcl2- tumours however respond to treatment,
probably through accumulation of DNA damage, abnormal
mitoses and subsequent mitotic catastrophe. The mechanisms
of mitotic catastrophe are unknown, but it likely results from a
combination of deﬁcient cell-cycle checkpoints (in particular
the DNA structure checkpoints and the spindle assembly
checkpoint) and cellular damage catastrophe. Conversely,
non-responding Bcl2- tumours could escape the response
through accumulation of genetic abnormalities that would not
lead to a mitotic catastrophe but rather to aneuploidy and
subsequent growth advantage. Interestingly, we found that loss
of Bcl2 in TNBC was associated with higher mitotic index, low
levels of p27 (G0/G1 check protein), MDM4 (p53-inhibitory
factor) and SPAG5 which is essential for cell cycle progression
and ﬁdelity of chromosomal segregation.
Bcl2-/LANBC patients treated with neoadjuvant ATC-CT are
more likely to have a pCR than Bcl2+ patients. However, in
those patients who do not achieve a pCR prognosis is worse in
the Bcl2- group. Clearly, these Bcl2- patients represent a cohort
who has demonstrated limited response to anthracycline-based
treatment and targeting alternative pathways in these patients
warrants further investigation.
We found that loss of Bcl2 expression in TNBC was
signiﬁcantly related to increased levels of CK19, P-cadherin,
E-cadherin and HER3. The differential expression of these
biomarkers could be a reﬂection of the molecular subclasses of
TNBC and could also have biological and therapeutic
implications. Previous studies have suggested P-cadherin as a
promising antibody therapeutic target or as a possible target for
immunotherapy of pancreatic, gastric and colorectal cancers
relapse. In agreement with an early study in basal BC, 75% of
our TNBC showed overexpression of P-cadherin and that is
highly associated with loss of Bcl2 compared with 35% of mixed
BC. Given the high incidence of P-cadherin overexpression in
TNBC Bcl2- tumours and that was associated with poor clinical
outcome (data not shown), P-cadherin targeting may warrant
further investigation in this group of TNBC.
Given that ∼40% of our TNBC cases show overexpression of
HER3, and that this is highly associated with the absence of
Bcl2, suggests a potential role of HER3 targeting agents in
speciﬁc subtypes of TNBC. Recent studies suggest that
combination treatment with trastuzumab and pertuzumab may
be particularly efﬁcacious in HER2-ampliﬁed BC; however, no
data are available for TNBC particularly in the HER2-enriched
subgroup.
Although prognosis is better in Bcl2+/TNBC mortality rates
can still be in excess of 20% at 15 years. Our data demonstrate
that the beneﬁt seen in Bcl2-/TNBC in response to
anthracycline-based treatment is not observed in Bcl2+ patients.
This would suggest that a different treatment strategy is required
in these patients. In conclusion, adding Bcl2 to the panel of
markers used in current clinical practice (ER, PR and HER2)
could provide both prognostic and predictive information in
patients with TNBC. Patients with Bcl2-/TNBC phenotype have
a worse prognosis than Bcl2+/TNBC patients but appear to
beneﬁt from ATC-CT. The optimal management of Bcl2
+/TNBC tumours is yet to be deﬁned. A prospective study is
required to validate these results and to investigate potential
therapeutic targets in Bcl2+/TNBC patients. In addition, Bcl2
status could be investigated as a possible predictive marker for
chemotherapy in non-TNBC high-risk BC subsets.
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